IL207530A - Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug - Google Patents

Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug

Info

Publication number
IL207530A
IL207530A IL207530A IL20753010A IL207530A IL 207530 A IL207530 A IL 207530A IL 207530 A IL207530 A IL 207530A IL 20753010 A IL20753010 A IL 20753010A IL 207530 A IL207530 A IL 207530A
Authority
IL
Israel
Prior art keywords
substituted
group
triazolyl
nitrogen
moiety
Prior art date
Application number
IL207530A
Other languages
English (en)
Hebrew (he)
Other versions
IL207530A0 (en
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL207530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IL207530A0 publication Critical patent/IL207530A0/en
Publication of IL207530A publication Critical patent/IL207530A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL207530A 2008-02-21 2010-08-10 Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug IL207530A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21
PCT/US2009/034447 WO2009105500A1 (en) 2008-02-21 2009-02-19 Compounds that are erk inhibitors

Publications (2)

Publication Number Publication Date
IL207530A0 IL207530A0 (en) 2010-12-30
IL207530A true IL207530A (en) 2014-08-31

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL207530A IL207530A (en) 2008-02-21 2010-08-10 Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug

Country Status (23)

Country Link
US (1) US8716483B2 (OSRAM)
EP (1) EP2260031B1 (OSRAM)
JP (1) JP5276676B2 (OSRAM)
KR (1) KR20100117123A (OSRAM)
CN (1) CN102015693B (OSRAM)
AR (1) AR070460A1 (OSRAM)
AU (1) AU2009215534B8 (OSRAM)
BR (1) BRPI0908120A8 (OSRAM)
CA (1) CA2714479A1 (OSRAM)
CL (1) CL2009000394A1 (OSRAM)
CO (1) CO6300939A2 (OSRAM)
EC (1) ECSP10010415A (OSRAM)
ES (1) ES2556353T3 (OSRAM)
IL (1) IL207530A (OSRAM)
MX (1) MX2010009268A (OSRAM)
MY (1) MY152271A (OSRAM)
NZ (1) NZ587504A (OSRAM)
PE (1) PE20091491A1 (OSRAM)
RU (1) RU2525389C2 (OSRAM)
SG (1) SG188179A1 (OSRAM)
TW (1) TWI398441B (OSRAM)
WO (1) WO2009105500A1 (OSRAM)
ZA (2) ZA201005909B (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7807672B2 (en) 2006-02-16 2010-10-05 Schering Corporation Compounds that are ERK inhibitors
EP2316031B1 (en) 2008-08-19 2016-09-14 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
US8999957B2 (en) * 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
CN103270029B (zh) 2010-10-22 2016-01-20 拜耳知识产权有限责任公司 作为农药的杂环化合物
EP2640421A4 (en) * 2010-11-16 2014-05-28 Medimmune Llc THERAPIES FOR TREATMENTS WITH ANTI-IGF ANTIBODIES
WO2013015918A1 (en) 2011-07-22 2013-01-31 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
AU2013225737B2 (en) 2012-03-01 2018-03-01 Array Biopharma Inc. Serine/threonine kinase inhibitors
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN103570630B (zh) * 2012-07-18 2016-04-20 广东东阳光药业有限公司 氮杂环衍生物及其在药物中的应用
EP2900241B1 (en) * 2012-09-28 2018-08-08 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2900223B1 (en) 2012-09-28 2017-10-25 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
AR095365A1 (es) * 2013-03-13 2015-10-14 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
RS57058B1 (sr) 2013-10-03 2018-05-31 Kura Oncology Inc Ekr inhibitori i postupci primene
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
KR20170095972A (ko) 2014-12-18 2017-08-23 머크 샤프 앤드 돔 코포레이션 제약 제제용 (s)-n-(3-(6-이소프로폭시피리딘-3-일)-1h-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2h)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 조성물
CA2971088A1 (en) * 2014-12-19 2016-06-23 Merck Sharp & Dohme Corp. (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
EP3277690B1 (en) * 2015-04-03 2020-02-26 Recurium IP Holdings, LLC Spirocyclic compounds
US20180250232A1 (en) * 2015-09-03 2018-09-06 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
BR112022006791A2 (pt) 2019-10-09 2022-06-28 Bayer Ag Novos compostos heteroaril-triazol como pesticidas
WO2021110168A1 (zh) 2019-12-06 2021-06-10 南京明德新药研发有限公司 作为erk抑制剂的螺环类化合物及其应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
WO2001056557A2 (en) 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of erk
BR0104424A (pt) 2000-02-05 2002-01-08 Vertex Pharma Composições de pirazol úteis como inibidores de erk
AU2001247372A1 (en) 2000-03-15 2001-09-24 Warner Lambert Company 5-amide substituted diarylamines as mex inhibitors
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US20050009876A1 (en) 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
ATE335737T1 (de) 2000-09-15 2006-09-15 Vertex Pharma Isoxazole und ihre verwendung als erk-inhibitoren
ATE346064T1 (de) 2000-09-15 2006-12-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
ES2279837T3 (es) 2000-11-20 2007-09-01 Scios Inc. Inhibidores de tipo piperidina/piperazina de la quinasa p38.
ATE354573T1 (de) 2000-12-21 2007-03-15 Vertex Pharma ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
CA2440842A1 (en) 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
EP1390353A1 (en) 2001-04-27 2004-02-25 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
WO2002088090A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
CA2456192A1 (en) 2001-08-03 2003-02-13 Qing Tang Pyrazole-derived kinase inhibitors and uses thereof
EP1423380B1 (en) 2001-08-03 2010-12-15 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
AU2002359291C1 (en) 2001-10-23 2008-11-20 Merck Serono Sa Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
AU2003233605A1 (en) 2002-05-24 2003-12-12 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
JP4845379B2 (ja) 2002-09-19 2011-12-28 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
WO2004083203A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
WO2005051308A2 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Methods of treating diseases and disorders by targeting multiple kinases
CA2548951A1 (en) 2003-12-22 2005-07-14 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
JP2007530595A (ja) 2004-03-26 2007-11-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｅｒｋ２のピリジンインヒビターおよびそれらの使用
US20070208015A1 (en) 2004-04-13 2007-09-06 Astex Therapeutics, Ltd. 5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38 MAP Kinase Modulators
EP3305776B1 (en) 2004-05-14 2019-09-25 Vertex Pharmaceuticals Incorporated Pyrrole compounds as inhibitors of erk protein kinases and pharmaceutical compositions containing these compounds
JP4993604B2 (ja) 2004-05-14 2012-08-08 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリルピリミジンｅｒｋプロテインキナーゼインヒビターのプロドラッグ
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
JP2008525461A (ja) 2004-12-23 2008-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ｅｒｋプロテインキナーゼの選択的阻害剤およびその使用
CN100377868C (zh) 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CA2633023C (en) 2005-12-13 2015-11-24 Schering Corporation Polycyclic indazole derivatives that are erk inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
US7807672B2 (en) 2006-02-16 2010-10-05 Schering Corporation Compounds that are ERK inhibitors
US20090062355A1 (en) 2006-04-20 2009-03-05 Takeda Pharmaceutical Company Limited Pharmaceutical Product
US7601852B2 (en) 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
US7884107B2 (en) 2006-06-30 2011-02-08 Merck Substituted piperidines that increase P53 activity and the uses thereof
US7671832B2 (en) 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
EA017865B1 (ru) 2007-03-28 2013-03-29 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
KR20100025553A (ko) * 2007-06-05 2010-03-09 쉐링 코포레이션 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도
SG182187A1 (en) 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
EP2170893A1 (en) 2007-06-18 2010-04-07 Schering Corporation Heterocyclic compounds and use thereof as erk inhibitors
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors

Also Published As

Publication number Publication date
SG188179A1 (en) 2013-03-28
CN102015693B (zh) 2014-10-29
CN102015693A (zh) 2011-04-13
ZA201005909B (en) 2014-03-26
ES2556353T8 (es) 2017-10-13
RU2010138635A (ru) 2012-03-27
ZA201400396B (en) 2014-12-23
AU2009215534A1 (en) 2009-08-27
WO2009105500A1 (en) 2009-08-27
EP2260031B1 (en) 2015-10-07
CO6300939A2 (es) 2011-07-21
JP2011513225A (ja) 2011-04-28
US8716483B2 (en) 2014-05-06
EP2260031A1 (en) 2010-12-15
BRPI0908120A2 (OSRAM) 2017-08-22
CL2009000394A1 (es) 2011-02-11
AU2009215534B8 (en) 2014-07-10
ECSP10010415A (es) 2010-09-30
KR20100117123A (ko) 2010-11-02
PE20091491A1 (es) 2009-09-25
NZ587504A (en) 2012-09-28
RU2525389C2 (ru) 2014-08-10
TWI398441B (zh) 2013-06-11
AU2009215534A2 (en) 2010-12-23
MX2010009268A (es) 2010-09-14
IL207530A0 (en) 2010-12-30
ES2556353T3 (es) 2016-01-15
MY152271A (en) 2014-09-15
US20110189192A1 (en) 2011-08-04
TW200948799A (en) 2009-12-01
AU2009215534B2 (en) 2014-06-26
AU2009215534A8 (en) 2014-07-10
AR070460A1 (es) 2010-04-07
BRPI0908120A8 (pt) 2017-10-24
JP5276676B2 (ja) 2013-08-28
CA2714479A1 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
IL207530A (en) Triazolyl-phenyl compounds and their use in the manufacture of a cancer treatment drug
AU2017232516B2 (en) Substituted inhibitors of menin-MLL and methods of use
KR102419524B1 (ko) 메닌-mll의 가교된 이환식 억제제 및 사용 방법
EP2694515B1 (en) Protein kinase inhibitors
RU2008128119A (ru) Новые соединения, действующие как ингибиторы erk
JP6277198B2 (ja) 置換インドール−５−オール誘導体及びそれらの治療適用
RU2009148867A (ru) Полициклические производные индазола и их применение в качестве ингибиторов erk для лечения рака
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
NZ596487A (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES AND THE USE THEREOF AS PI3K INHIBITORS
CN116217581A (zh) 用于抑制多发性内分泌抑癌蛋白与mll蛋白质的相互作用的方法及组合物
RU2018134981A (ru) Конъюгаты, содержащие ингибиторы RIPK2
CN120092009A (zh) 包含6-氮杂部分的氧氮杂䓬化合物及其用途
CN114599361A (zh) Prmt5抑制剂的药物组合物
IL274936B2 (en) Transmuted heterocyclic bicyclic compounds as prmt5 inhibitors
WO2008007123A3 (en) Pharmaceutical compounds
JP2010538091A5 (OSRAM)
Batran et al. Design, synthesis, and molecular modeling of quinoline‐based derivatives as anti‐breast cancer agents targeting EGFR/AKT signaling pathway
JPWO2020032105A5 (OSRAM)
RU2013120357A (ru) Фармацевтические комбинации
CA3107548A1 (en) Smad3 inhibitors
CA3136492A1 (en) Heterocyclic compounds and uses thereof
JP2019537598A (ja) ２−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
Husseiny et al. Aminopyridone-linked benzimidazoles: a fragment-based drug design for the development of CDK9 inhibitors
Ali et al. Convenient synthesis and anti-proliferative activity of some benzochromenes and chromenotriazolopyrimidines under classical methods and phase transfer catalysis
RU2006106768A (ru) Новые ингибиторы фарнезилпротеинтрансферазы как противоопухолевые агенты

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed